These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
228 related articles for article (PubMed ID: 36971193)
1. Updated insights on dementia-related risk of sacubitril/valsartan: A real-world pharmacovigilance analysis. Chen C; Ding L; Fu F; Xiao J CNS Neurosci Ther; 2023 Sep; 29(9):2548-2554. PubMed ID: 36971193 [TBL] [Abstract][Full Text] [Related]
2. Dementia-related adverse events in PARADIGM-HF and other trials in heart failure with reduced ejection fraction. Cannon JA; Shen L; Jhund PS; Kristensen SL; Køber L; Chen F; Gong J; Lefkowitz MP; Rouleau JL; Shi VC; Swedberg K; Zile MR; Solomon SD; Packer M; McMurray JJ; Eur J Heart Fail; 2017 Jan; 19(1):129-137. PubMed ID: 27868321 [TBL] [Abstract][Full Text] [Related]
3. Cognition- and Dementia-Related Adverse Effects With Sacubitril-Valsartan: Analysis of the FDA Adverse Event Report System Database. Perlman A; Hirsh Raccah B; Matok I; Muszkat M J Card Fail; 2018 Aug; 24(8):533-536. PubMed ID: 29746915 [TBL] [Abstract][Full Text] [Related]
4. Five Years of Sacubitril/Valsartan-a Safety Analysis of Randomized Clinical Trials and Real-World Pharmacovigilance. Kim YS; Brar S; D'Albo N; Dey A; Shah S; Ganatra S; Dani SS Cardiovasc Drugs Ther; 2022 Oct; 36(5):915-924. PubMed ID: 34125356 [TBL] [Abstract][Full Text] [Related]
5. Angioedema with sacubitril/valsartan: Trial-level meta-analysis of over 14,000 patients and real-world evidence to date. Dani SS; Ganatra S; Vaduganathan M Int J Cardiol; 2021 Jan; 323():188-191. PubMed ID: 32841619 [TBL] [Abstract][Full Text] [Related]
6. Sacubitril/valsartan and the risk of incident dementia in heart failure: a nationwide propensity-matched cohort study. Lee HJ; Kim HK; Kim BS; Han KD; Kwak S; Park CS; Rhee TM; Park JB; Lee H; Kim YJ Clin Res Cardiol; 2024 Jun; 113(6):875-883. PubMed ID: 37906294 [TBL] [Abstract][Full Text] [Related]
7. Adverse events with sacubitril/valsartan in the real world: emerging signals to target preventive strategies from the FDA adverse event reporting system. Gatti M; Antonazzo IC; Diemberger I; De Ponti F; Raschi E Eur J Prev Cardiol; 2021 Aug; 28(9):983-989. PubMed ID: 34402868 [TBL] [Abstract][Full Text] [Related]
8. Diarrhoea with the angiotensin receptor neprilysin inhibitor sacubitril + valsartan: A pharmacovigilance study. Guion-Firmin J; Tessier S; Lepelley M; Faillie JL; Montastruc JL Fundam Clin Pharmacol; 2022 Apr; 36(2):378-389. PubMed ID: 34260768 [TBL] [Abstract][Full Text] [Related]
9. The real-world safety of sacubitril / valsartan among older adults (≥75): A pharmacovigilance study from the FDA data. Lerman TT; Greenberg N; Fishman B; Goldman A; Talmor-Barkan Y; Bauer M; Goldberg I; Goldberg E; Kornowski R; Krause I; Levi A; Cohen E Int J Cardiol; 2024 Feb; 397():131613. PubMed ID: 38030039 [TBL] [Abstract][Full Text] [Related]
10. Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. Solomon SD; McMurray JJV; Anand IS; Ge J; Lam CSP; Maggioni AP; Martinez F; Packer M; Pfeffer MA; Pieske B; Redfield MM; Rouleau JL; van Veldhuisen DJ; Zannad F; Zile MR; Desai AS; Claggett B; Jhund PS; Boytsov SA; Comin-Colet J; Cleland J; Düngen HD; Goncalvesova E; Katova T; Kerr Saraiva JF; Lelonek M; Merkely B; Senni M; Shah SJ; Zhou J; Rizkala AR; Gong J; Shi VC; Lefkowitz MP; N Engl J Med; 2019 Oct; 381(17):1609-1620. PubMed ID: 31475794 [TBL] [Abstract][Full Text] [Related]
11. Association of Heart Failure Patients With and Without Sacubitril-Valsartan Use With Incident Cancer Risk. Hu WS; Lin CL J Cardiovasc Pharmacol; 2023 Aug; 82(2):157-161. PubMed ID: 37133967 [TBL] [Abstract][Full Text] [Related]
14. Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction: Rationale and Design of the PARAGON-HF Trial. Solomon SD; Rizkala AR; Gong J; Wang W; Anand IS; Ge J; Lam CSP; Maggioni AP; Martinez F; Packer M; Pfeffer MA; Pieske B; Redfield MM; Rouleau JL; Van Veldhuisen DJ; Zannad F; Zile MR; Desai AS; Shi VC; Lefkowitz MP; McMurray JJV JACC Heart Fail; 2017 Jul; 5(7):471-482. PubMed ID: 28662936 [TBL] [Abstract][Full Text] [Related]
15. Potential Safety Signals for Rhabdomyolysis Associated With High-Potency Statin Use With or Without Sacubitril/Valsartan. Sunaga T; Ryo Y Am J Cardiol; 2022 Mar; 166():127-130. PubMed ID: 34963512 [TBL] [Abstract][Full Text] [Related]
16. Signal mining and analysis for central nervous system adverse events due to taking oxycodone based on FAERS database. Wu X; Zhang L; Huang H; Huang L; Lu X; Wang Z; Xiao J Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2023 Mar; 48(3):422-434. PubMed ID: 37164926 [TBL] [Abstract][Full Text] [Related]
17. Neprilysin inhibition with sacubitril/valsartan in the treatment of heart failure: mortality bang for your buck. Ansara AJ; Kolanczyk DM; Koehler JM J Clin Pharm Ther; 2016 Apr; 41(2):119-27. PubMed ID: 26992459 [TBL] [Abstract][Full Text] [Related]
18. Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF. Böhm M; Young R; Jhund PS; Solomon SD; Gong J; Lefkowitz MP; Rizkala AR; Rouleau JL; Shi VC; Swedberg K; Zile MR; Packer M; McMurray JJV Eur Heart J; 2017 Apr; 38(15):1132-1143. PubMed ID: 28158398 [TBL] [Abstract][Full Text] [Related]
19. Sacubitril/Valsartan: The Newest Addition to the Toolbox for Guideline-Directed Medical Therapy of Heart Failure. Rodgers JE Am J Med; 2017 Jun; 130(6):635-639. PubMed ID: 28285069 [TBL] [Abstract][Full Text] [Related]